

**ASH CLINICAL PRACTICE GUIDELINES** SICKLE CELL DISEASE (SCD)

# Stem Cell Transplantation for Sickle Cell Disease

**An Educational Slide Set** 

American Society of Hematology 2021 Guidelines for Sickle Cell Disease Stem Cell Transplantation

Slide Set Authors:

Akshay Sharma, MBBS, St. Jude Children's Research Hospital, Memphis, TN and John Tisdale, MD, Cellular and Molecular Therapeutics Branch, NHLBI, National Institutes of Health, Bethesda, MD





#### **Clinical Guidelines**

American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation

Julie Kanter, Robert I. Liem, Francoise Bernaudin, Javier Bolanos-Meade, Courtney D. Fitzhugh, Jane S. Hankins, M. Hassan Murad, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, John Wagner, Mark C. Walters, Teonna Woolford, Joerg J. Meerpohl, and John Tisdale

Julie Kanter, Robert I. Liem, Françoise Bernaudin, Javier Bolaños-Meade, Courtney D. Fitzhugh, Jane S. Hankins, M. Hassan Murad, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, John Wagner, Mark C. Walters, Teonna Woolford, Joerg J. Meerpohl, John Tisdale; American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. *Blood Adv* 2021; 5 (18): 3668–3689. doi: https://doi.org/10.1182/bloodadyances.2021004394C

CLINICAL GUID	ELINES	© blood advance
American So stem cell tran		idelines for sickle cell disease:
		<sup>5</sup> Courtney D. Fitzhugh, <sup>6</sup> Jane S. Hankins, <sup>7</sup> M. Hassan Murad lark C. Walters, <sup>13</sup> Teonna Woolford, <sup>14</sup> Joerg J. Meerpohl, <sup>15</sup>
Children's Hospital of Chicago, Française de Groffe de Moelle e Therapeutics Branch, National Memphia, TN; "Division of Preve of Hematology-Oncology, Unive and Marrow Transplantation, De <sup>14</sup> Sickle Cell Reproductive Hea	Chicago, IL; <sup>9</sup> French Referral Center for Sickle Call Disease, Cent da Threipia Calluaire, Lillo, Fnano; <sup>9</sup> Dapatroment of Oncology, John eart, Lung and Bood Institute, National Institutes of Health, Bethe ntire Medicine, Mayo Clinic, Ricchester, Mik <sup>®</sup> , <sup>4</sup> Medical Collego of W raity of Illinois at Chicago, Chicago, E.; <sup>11</sup> SI Louis Children <sup>1</sup> s Hospit patrenet of Pediatrice, University of Minnesota, Minnesota, Minnesota, Min.	on of Henstology, Orozlogy and Siem Cali Tarangiant, Ann A Robert H. Lu Hospitalin Informational Criticu, University Paris, R. Paris, Tarone, "Scool e Hopkins University School of Medicine, Bathrore, MD, "Califar and Meloca da, MD, "Department of Homatology, S. Jako Chidan's Research Hospital scorain/Chiden's Wisconsin, Pediate: Hensitology, Minausen, WI, "Dissi Washington University School of Medicine, Status, MD, "Division of Bio Beneff Chiden's Hospital, University of California San Francisco, Oakland, C Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg
	significant complications and affects qu	) is a life-limiting inherited hemoglobinopathy that results ality of life. Hematopoietic stem cell transplantation (HSC for SCD; however, guidelines are needed to inform how
		nes of the American Society of Hematology (ASH) are intende professionals in their decisions about HSCT for SCD.
	was balanced to minimize potential bias Research Program supported the guideli dence reviews (through 2019). The pane importance for clinicians and patients. Th Development and Evaluation (GRADE) aj	panel formed by ASH included 2 patient representatives ar from conflicts of interest. The Mayo Evidence Based Practic ed evelopment process, including performing systematic ex- prioritized clinical questions and outcomes according to the enanel used the Grading of Recommendations Reseasmer protect, including GRADE Evidence to Decision framework dations, which were subject to public comment.
		ommendations to help patients and providers assess ho
	Conclusions: The evidence review yield therefore, all recommendations are base include considering HSCT for those with	ted no randomized controlled clinical trials for HSCT in SCI d on very low certainty in the evidence. Key recommendation neurologic injury or recurrent acute chest syndrome at an ear jmens. Future research should include the development of
	Summary of recommendati	ons
	States. Individuals with SCD are affected in morbidities and early mortality. Hematopoin lished curative intervention for SCD that ca tology (ASH) guideline panel addressed q	non inherited clinically significant hemoglobinopathy in the Unit y multiple disease-related complications that result in significa tic stem cell transplantation (HSCT) is currently the only estal nestron nomal hematopoiesis. The American Society of Hem setions related to the use of HSCT for patients with SCD wi is workowe (ASS). The panel allo addressed patients

Submitted 28 January 2021; accepted 23 June 2021; final version published online 28 Th September 2021, DOI 10.1182/bloodadvances.2021004394. C

3668 KANTER





#### ASH Clinical Practice Guidelines on SCD

- 1. Cardiopulmonary and Kidney Disease
- 2. Transfusion Support
- 3. Cerebrovascular Disease
- 4. Acute and Chronic Pain
- **5. Stem Cell Transplantation**





#### How were these ASH guidelines developed?

#### **PANEL FORMATION**

Each **guideline panel** was formed following these key criteria:

- Balance of expertise (including disciplines beyond hematology, and patients)
- Close attention to minimization and management of conflicts of interest

CLINICAL QUESTIONS 10 clinically-relevant questions generated in PICO format (population, intervention, comparison, outcome)

**Example: PICO question** "Should individuals with SCD and neurologic injury, including overt stroke, SCI, or abnormal TCD, undergo MSD transplantation??"

#### **EVIDENCE SYNTHESIS**

Evidence summary generated for each PICO question via systematic review of health effects plus:

- Resource use
- Feasibility
- Acceptability
- Equity
- Patient values and preferences

#### MAKING RECOMMENDATIONS

Recommendations made by guideline panel members based on evidence for all factors.

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources, such as this slide set, derived from guidelines that require updating are removed from the ASH website.





#### How to use these recommendations

	STRONG Recommendation ("The panel recommends")	<b>CONDITIONAL Recommendation</b> ("The panel suggests")
For patients	Most individuals would want the intervention.	A majority would want the intervention, but many would not.
For clinicians	Most individuals should receive the intervention.	Different choices will be appropriate for different patients, depending on their values and preferences. Use <b>shared</b> <b>decision making</b> .





#### Key terms: SCD related adverse events

- Stroke
  - acute neurologic injury of the brain, retina, or spinal cord that occurs as a result of ischemia or hemorrhage that last longer than 24 hours.
- Silent cerebral infarction (SCI)/silent stroke
  - a lesion visible by magnetic resonance imaging (MRI) images with no associated findings on neurologic exam.
  - can be correlated with neurocognitive and behavioral deficits.
- Acute chest syndrome (ACS)
  - a new radiodensity on chest radiograph together with fever and/or respiratory symptoms.





#### Key terms in stem cell transplantation

- Matched donor
  - A donor who is at least identical to the recipient at 8/8 or 10/10 human leucocyte antigen (HLA) loci.
  - A matched donor can be a sibling (matched sibling donor or MSD) or unrelated (matched unrelated donor or MUD).
- Graft versus host disease (GVHD)
  - An immunological complication of allogeneic hematopoietic stem cell transplantation (HSCT).
- Graft failure
  - A condition wherein the blood cell counts decrease following HSCT, or the proportion of the donor cells declines below a critical level in the peripheral blood and bone marrow.





## Objectives

By the end of this session, you should be able to:

- Describe recommendations for HSCT in individuals with SCD in high-income settings.
- Describe recommendations for choice of:
  - conditioning regimen
  - alternative donor
  - graft source
- ... in individuals undergoing HSCT for SCD.





Background and Introduction





#### Comparing HSCT and Standard of Care for SCD

- HSCT is a potential 1-time curative therapy for SCD.
- HSCT for SCD is evolving new conditioning regimens, alternative donors and methods of cell harvesting, and strategies for GVHD prevention.
- Success rates after HSCT are improving, **but** survival rates in children and adults with SCD receiving disease-modifying medication and supportive therapy are improving as well.
- Short- and long-term risks of HSCT must be considered in comparison to the currently approved therapies and new potentially curative therapies under development.



#### **ASH CLINICAL PRACTICE GUIDELINES** SICKLE CELL DISEASE (SCD)



#### Risk of HSCT related complications with age

nsplantation-related complications		<ul> <li>Viral infections (eg, cytomegalovirus, adenovirus, and human herpesvirus 6)</li> <li>Challenging pharmacokinetics</li> <li>Almost no sickle cell disease-related mortality and a controlled morbidity</li> <li>Risk of veno-occlusive disease or sinusoidal obstruction syndrome</li> </ul>	<ul> <li>Little risk of iron overload</li> <li>Few irreversible sickle cell disease-related complications</li> <li>Low risk of veno-occlusive disease or sinusoidal obstruction syndrome</li> <li>Patient can provide consent</li> <li>Fertility preservation options available</li> </ul>	<ul> <li>Transplantation-associated systemic vasculopathy:</li> <li>Neurotoxicity and posterior reversible encephalopathy syndrome</li> <li>Veno-occlusive disease or sinusoidal obstruction syndrome</li> <li>Acute and chronic GVHD</li> <li>Alloimmunisation</li> <li>Delayed immune reconstitution</li> <li>Graft rejection</li> <li>High transplantation-related motality</li> <li>Irreversible sickle cell disease-related complications</li> </ul>
Risk of tr		Matched sibling donor HSCT, matched unrelated donor HSCT, or haploidentical HSCT*	Matched unrelated donor HSCT or haploidentical HSCT*	Haploidentical HSCT or gene editing and gene therapy options
	~	3 ~5 ~1	I .0 ~	18 >~40
			Age of the recipient (years)	

de la Fuente et al. Lancet Haematol 2020.





#### Case 1: Patient with neurological injury

A 4-year-old male with HbSS living in the United States, presents to your clinic for an annual visit. The child has recently had two abnormal TCD measurements (high MCA velocity). He is receiving hydroxyurea with good compliance since he was 2 years old. He has an HLA-matched 8-year-old sibling who has sickle cell trait. What is the next best step?

- A. Repeat TCD in 1 year.
- B. Continue hydroxyurea, but increase the dose.
- C. Start transfusion/apheresis to reduce sickle hemoglobin level.
- D. Discuss hematopoietic cell transplantation using the HLA-matched sibling as a donor.





## HSCT for SCD patients with neurological injury: Recommendations

- HLA-matched related HSCT is suggested over standard of care (hydroxyurea/transfusion) in patients with SCD who have experienced an overt stroke or have an abnormal transcranial Doppler ultrasound (TCD) (conditional recommendation. very low certainty in the evidence).
- When considering transplantation for neurologic injury, children younger than age 16 years who receive matched sibling donor (MSD) HSCT have better outcomes than those older than age 16 years.



#### HSCT for SCD patients with neurological injury: Rationale


- Neurologic injury caused by overt stroke and SCI is a major complication of SCD.
- Up to 24% SCD patients could be affected by stroke.
- Chronic red cell transfusion (CRCT) and other supportive care therapy are useful in stroke prevention but not curative.
- Long-term CRCT is associated with risks such as alloimmunization and transfusional iron overload.
- Therefore, efforts to prevent primary or secondary stroke have focused on curative options such as HSCT.





#### HSCT vs CRCT for SCD patients with neurological injury

Figure 2. Time Course of Velocity and MRA Score Outcomes During the 3-Year Follow-up in Both Groups After Matching on Propensity Score Including Siblings Without SCA, Age, and Sex



TCD improved in those who received HSCT. New SCI developed in 3 patients who were receiving CRCT.

Bernaudin et al. JAMA 2019.





#### Case 2: Patient with severe symptoms

A 9-year-old female with HbSβ<sup>0</sup> thalassemia has had 2 episodes of acute chest syndrome in the last 1 year. During the last episode, she required intensive care treatment and intubation. She has 3 siblings who do not have SCD. What is the next best step?

- A. Continue current management.
- B. Refer for gene therapy on a clinical trial.
- C. Start transfusion/apheresis to reduce sickle hemoglobin level.
- D. Perform HLA typing of the siblings to find a potential donor for HSCT.






# HSCT for SCD patients with severe symptoms: Recommendations

- For patients with frequent pain or recurrent episodes of acute chest syndrome, consideration for transplantation should be given to patients who do not respond or have an inadequate response to standard of care, such as HU, new targeted therapies, or chronic transfusion therapies.
- For patients with SCD with an indication for HSCT **who lack an MSD**, suggest using transplants from alternative donors in the context of a clinical trial.
  - Alternative donor transplantation has the potential to improve or resolve disease manifestations in patients with severe SCD.
  - The risks related to transplantation complications should be balanced with benefits derived from successful transplantation.







Eapen et al. Lancet Haematology 2019.





#### HSCT for SCD patients with severe symptoms: Rationale

- Patient-reported outcomes of pain intensity and pain impact improved post-HSCT in a subset of patients with only intermittent pain pre-HSCT.
- However, some patients (~40%) continue to experience pain post-HSCT. HSCT may not ameliorate chronic pain.
- ACS events no longer occur in patients in whom HSCT is successful.
- HSCT offers prospect of improved quality of life and prolonged survival when standard of care therapy is not successful.





# Considerations for an allogeneic HSCT (conditional recommendations)

- Suggest using either total-body irradiation (TBI) #400 cGy or chemotherapy-based conditioning regimens for allo HSCT.
- In children with MSD, use myeloablative conditioning regimens over reduced intensity conditioning (RIC).
- In adults with MSD, use non-myeloablative conditioning over RIC.
- In patients with an indication, perform transplant at an earlier age than at an older age (no recommendation if no MSD available, impact of age on outcome may be related to conditioning regimen used).
- If HLA-identical sibling cord blood unit is available with good cell dose and viability, it is preferred over bone marrow .





### Considerations for an allogeneic HSCT: Conditioning regimen

- Chemotherapy-based myeloablative conditioning with busulfan and cyclophosphamide, with or without serotherapy with anti-thymocyte globulin, is the standard of care for **pediatric patients** with SCD undergoing MSD HSCT.
  - Incidence of graft failure is higher after RIC compared to myeloablative conditioning.
- Nonmyeloablative regimens based on low-dose TBI have been developed and seem highly effective in reversing the disease in **adult patients**.
  - Better tolerated than chemotherapy-based conditioning in adults.
  - Potential for fertility preservation.





### Age at HSCT and relationship to conditioning intensity

- With **myeloablative conditioning**, EFS was highest in children younger than age 13 years and with an MSD.
- Patients older than age 13 years had not only lower EFS but also lower OS and higher chronic GVHD risk.
- With myeloablative conditioning, the risk of chronic GVHD is significantly higher in those older than 15 years of age.
- Nonmyeloablative conditioning demonstrated no chronic GVHD or associated transplantation-related mortality.
- However, EFS was only 87%, because 13% had graft rejection.






#### Risk score to predict outcomes after HSCT

#### Table 1. Risk score based on age at transplantation and type of donor (training cohort)

					3-year probability/incidence % (95% CI)		
Age, y	Age score	Type of donor	Donor score	Total score	EFS	Death without graft failure	Graft failure
≤12	0	HLA matched sibling	0	0	92 (89-94)	2 (0-4)	6 (4-9)
	0	HLA mismatched relative	2	2	62 (43-76)	8 (2-19)	30 (15-47)
	0	Matched unrelated donor	1	1	83 (69-91)	8 (2-18)	8 (2-18)
	0	Mismatched unrelated donor	2	2	68 (55-79)	5 (1-13)	27 (16-38)
≥13	1	HLA matched sibling	0	1	87 (81-92)	7 (4-11)	5 (2-10)
	1	HLA mismatched relative	2	3	52 (38-65)	10 (4-18)	38 (24-51)
	1	Matched unrelated donor	1	2	50 (34-64)	29 (17-43)	21 (10-33)
	1	Mismatched unrelated donor	2	3	49 (31-66)	23 (9-40)	28 (13-44)



Years after HCT

Brazauskas et al. Blood 2020.





#### Cord blood transplantation

- Neutrophil and platelet recovery delayed after cord blood transplantation compared to bone marrow transplantation, but no increase in infections or non engraftment.
- Trend towards lower acute and chronic GVHD with cord blood transplantation.
- No difference in overall survival or event free survival with cord blood transplantation.
- Hence cord blood transplantation preferred over bone marrow for SCD, provided sufficient cell dose is available.





#### **Good Practice Statements**

- 1. Ensure that potential patients have been seen and counseled by an SCD specialist in addition to a specialist in HSCT to review all available treatment options.
- 2. Providers should be adequately trained in the specialized care required by SCD patients, including supportive care, which differs from that of other disease states.
- 3. Disease and transplantation-related outcomes should be monitored in the short (<2 years) and long term (10-15 years) in all patients after HSCT.
- 4. Care providers should consider health literacy levels of patients and their families when advising on HSCT.
- 5. Care providers should consider the burdens of the HSCT procedure on patients and their families.
- 6. Shared decision making between patients and providers is suggested to establish optimal HSCT plans.





- ASH guideline panel members
- Mayo Clinic Evidence-Based Practice Research Program
- ASH support team: Starr Webb, Kendall Alexander, Robert Kunkle
- See more about the ASH SCD guidelines: <u>https://hematology.org/SCDguidelines</u>
- Disclosures: Akshay Sharma is the St. Jude Children's Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287) and by Novartis (NCT04443907). The industry sponsors provide funding for the clinical trial, which includes salary support paid to Akshay Sharma's institution. Akshay Sharma has received consultant fee from Spotlight Therapeutics, Medexus Inc. and Vertex Pharmaceuticals. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education.